打破致癌联盟:在癌症治疗中破坏MTDH-SND1复合物的进展
Noha A Ahmed1, Ahmed A Allam2, Hassan A Rudayni2
1Physiology Division, Zoology Department, Faculty of Science, Beni-Suef University P.O. Box 62521 Beni-Suef Egypt drnohascience@science.bsu.edu.eg.
RSC advances
|August 28, 2025
概括
向甲素 (MTDH) 和葡萄球菌核酶域含蛋白1 (SND1) 的合作关系显示出癌症治疗的前景. 通过抑制关键癌症途径, 破坏这种致癌中心可以减少瘤生长和转移.
科学领域:
- 癌症学
- 分子生物学
- 药物发现
背景情况:
- 甲素 (MTDH) 和葡萄球菌核酶域含有蛋白1 (SND1) 形成了一个关键的致癌复合体.
- 这种MTDH-SND1轴驱动各种癌症的瘤增殖,存活和转移.
- 关键的信号通路如NF-κB,PI3K/Akt和Wnt/β-catenin是通过这种相互作用来调节的.
研究的目的:
- 审查MTDH-SND1相互作用的当前知识.
- 突出针对MTDH- SND1综合体作为抗癌策略的临床前证据.
- 调查MTDH-SND1干扰的治疗方法和未来方向.
主要方法:
- 关于MTDH- SND1抑制的临床前研究的巩固.
- 对MTDH-SND1结合接口进行映射的结构生物学发现的摘要.
- 对包括小分子,和新兴技术在内的治疗策略的调查.
主要成果:
- 对MTDH-SND1的遗传或药理阻断会减少原发性瘤的生长和转移.
- 结构研究确定治疗向的关键约束因素.
- 在临床前模型中,包括和小分子在内的各种干扰剂具有强烈的细胞毒性.
- 像PROTAC和先进药物输送等新兴策略显示出增强特异性和有效性的潜力.
结论:
- 破坏MTDH-SND1复合体是对抗治疗耐药癌症的有效策略.
- 通过抑制多种致癌途径,针对这种相互作用可以产生广泛的抗瘤效应.
- 克服毒性和生物可用性等挑战对于临床转化至关重要.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:46Electron Transport Chain: Complex I and II
15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.0K
01:10Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:15Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K